Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.CN |
First Approval Date08 Jan 2024 |
荆门上清丸治疗复发性口腔溃疡(上焦实热证)随机、双盲、安慰剂平行对照、多中心Ⅲ期临床试验
[Translation] A randomized, double-blind, placebo-controlled, multi-center phase III clinical trial of Jingmen Shangqing Pill in the treatment of recurrent oral ulcers (Shangjiao real heat syndrome)
以治疗5天后的靶溃疡愈合率为主要疗效指标,通过随机、双盲、安慰剂平行对照、多中心临床试验,确证荆门上清丸治疗复发性口腔溃疡(上焦实热证)的有效性和安全性。
[Translation] Taking the target ulcer healing rate after 5 days of treatment as the main curative effect index, the efficacy and safety of Jingmen Shangqing Pill in the treatment of recurrent oral ulcers (Shangjiao excess heat syndrome) were confirmed through a randomized, double-blind, placebo-controlled, multi-center clinical trial. safety.
评价荆门上清丸治疗复发性口腔溃疡的安全性和有效性随机、双盲、安慰剂平行对照、多中心临床试验
[Translation] A randomized, double-blind, placebo-controlled, multicenter clinical trial to evaluate the safety and efficacy of Jingmen Shangqing Pill in the treatment of recurrent oral ulcers
以安慰剂为对照,评价荆门上清丸治疗复发性口腔溃疡的有效性及安全性
[Translation] To evaluate the efficacy and safety of Jingmen Shangqing Pill in the treatment of recurrent oral ulcer with placebo as control
100 Clinical Results associated with Hubei Qijin Pharmaceutical Co., Ltd.
0 Patents (Medical) associated with Hubei Qijin Pharmaceutical Co., Ltd.
100 Deals associated with Hubei Qijin Pharmaceutical Co., Ltd.
100 Translational Medicine associated with Hubei Qijin Pharmaceutical Co., Ltd.